News | September 14, 2024
Briefs: RPG Life Sciences and Lasa Supergenerics
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Majority of organizations are looking to increase investments in public and hybrid cloud
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated
